Obermatt
See Similar Stocks →

Grail

NSQ:GRAL · US3847471014
BiotechnologyMedium

360

27
Profit price59
Cash yield1
Price/Sales35
EV / Gross Profit25
Price/Book70
Return on Capital63
Cash Return on Capital68
Return on Equity65
Profit margins47
Accruals42
Owner Earnings Margin36
Sales growth63
Profit growth6
Reinvestment17
Price momentum60
Debt load78
Refinancing51
Debt Payback1
Liquidity36
Analyst ratings19
Opinion Changes50
Price Target Upside12
Market mood25
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Grail clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded2015
Employees983
Websitegrail.com
ISINUS3847471014
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
OncologyGeneticsHealth DiagnosticsBiotechnologyHealth CareMedicalMedical Device

Description

GRAIL, Inc. (GRAIL), an innovative commercial-stage healthcare company, focuses on shifting the paradigm in early cancer detection at population scale. The company’s multi-cancer early detection test (‘Galleri’) can screen for many types of cancer,…

Analysis

Middle-of-the-road

GRAIL, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 10/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
30
2026

All-time high

40

Mar 2026

All-time low

30

Jun 2026

Average rank

35

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
35
—
—
—
Price/Earnings
71
—
—
—
Price/Book
70
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
89
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Grail with its peers
Exact Sciences
NAQ:EXAS
20
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Natera
NSQ:NTRA
39
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Geron
NSQ:GERN
22
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Whitehawk Therapeutics
NAQ:WHWK
38
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
enGene
NAQ:ENGN
—
CountryCanada
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Halozyme Therapeutics
NSQ:HALO
71
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →